Modality
Small Molecule
MOA
CAR-T BCMA
Target
PARP
Pathway
Angiogenesis
ACCProstate CaCTCL
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
~Feb 2018
→ ~May 2019
Phase 3
Aug 2019
→ Jul 2030
Phase 3Current
NCT04919990
2,676 pts·ACC
2019-08→2026-04·Active
NCT07127535
1,779 pts·CTCL
2021-12→2029-03·Completed
NCT05893622
500 pts·Prostate Ca
2020-05→2030-07·Terminated
4,955 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-04-112w awayPh3 Readout· ACC
2029-03-173.0y awayPh3 Readout· CTCL
2030-07-034.3y awayPh3 Readout· Prostate Ca
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Active
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2026-04-11 · 2w away
ACC
Ph3 Readout
2029-03-17 · 3.0y away
CTCL
Ph3 Readout
2030-07-03 · 4.3y away
Prostate Ca
ActiveCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04919990 | Phase 3 | ACC | Active | 2676 | ACR20 |
| NCT07127535 | Phase 3 | CTCL | Completed | 1779 | Mayo |
| NCT05893622 | Phase 3 | Prostate Ca | Terminated | 500 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |